DF-7001

N/A

Report date: 2022/05/06 10:23:23

Base Information

Drug NameDF-7001
Drug Alias NameDF-7001 TriNKET™DF-7001
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibody
Mechanisms of ActionAnti-Trophoblast glycoproteinFCGR3A (CD16a) NK-cell engagersNKG2D ligands modulators
TargetsTrophoblast glycoproteinLow affinity immunoglobulin gamma Fc region receptor III-ANKG2D ligands
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesDragonfly Therapeutics Llc
China Registration ClassN/A

Develop Information

Active CompaniesGilead Sciences IncDragonfly Therapeutics LlcThe University Of Texas MD Anderson Cancer Center
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A